NCT07467772 2026-04-21Ph 2 Elacestrant in ER Positive Uterine SarcomasDana-Farber Cancer InstitutePhase 2 Recruiting30 enrolled
NCT02834013 2026-04-13Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting818 enrolled